Sprouting angiogenesis is an invasive process that involves proteolytic activities required for the degradation of the endothelial basement membrane, cell migration with removal of obstructing matrix proteins, and generation of space in the matrix to allow endothelial cells to form a proper lumen. In the last decade it has become clear that besides these matrix-degrading properties, proteases exert additional, more subtle functions that play a key role in angiogenesis. These functions are discussed with specific emphasis on membrane type-1 matrix metalloproteinase (MT1-MMP), other MMPs, and the related ADAMs (a disintegrin and metalloproteinase domain). Proteases modulate the balance between pro-and anti-angiogenic factors by activation and modification of growth factors and chemokines, ectodomain shedding with accompanied receptor activation, shedding of cytokines from membrane-bound precursors, and generation of (matrix) protein fragments that inhibit or activate angiogenesis. Furthermore, they participate in the recruitment of leukocytes and progenitor cells, which contribute to the onset and progression of angiogenesis. Proteases facilitate the mobilization of progenitor cells in the bone marrow as well as the entry of these cells and leukocytes into the angiogenic area. The interaction between pericytes and the newly formed endothelial tubes is accompanied by silencing of MMP activities. Better understanding of the various activities of proteases may be helpful in developing more specific inhibitors that could result in tailor-made modification of proteolytic activities in disease.
INTRODUCTION
Many physiological and pathological conditions, such as development and growth, inflammation, tissue repair and tumor growth, induce a neovascularization response in order to cope with the increased oxygen and nutrient demand of the tissue 1 . This response starts when the induction of pro-angiogenic factors get the mastery of the anti-angiogenic factors that are present in the tissue, and is recognized as sprouting of microvascular vessels which finally organize in a new perfused vascular bed 2 . In a number of pathological conditions, in particular in tumors, massive angiogenic sprouting occurs, but the process remains stuck in the expansion phase resulting in a disorganized and poorly perfused neovasculature 3 . The process of angiogenesis is accompanied by the recruitment of circulating cells, which contribute to the neovascular growth by providing growth factors and occasionally by insertion of endothelial (progenitor) cells into the new vascular spouts 4, 5 .
Because sprouting angiogenesis is an invasive process, proteolytic activities are required 6, 7 . They are needed for the degradation of the basement membrane of endothelial cells allowing invasion into the tissue; for cell migration and removal of obstructing matrix proteins; and for creating space in the matrix to allow generation of endothelial cell tubules. However, in the last decade it has become clear that besides their substratespecific destructive properties, proteases exert more subtle functions that play a key role in angiogenesis, including the activation and modification of growth factors, cytokines and receptors, and the generation of matrix protein fragments that inhibit angiogenesis [6] [7] [8] [9] .
These effects of proteases are most prominently executed by proteases that act outside the cell, in particular at the cell surface, although several proteases within the cell at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from contribute indirectly to angiogenesis by mediating apoptosis, as well as by proenzyme activation and proteasomal degradation of e.g. hypoxia-inducible factor (HIF). All major classes of proteases harbor members that are involved in pericellular proteolysis, as schematically summarized in Figure 1 . It is likely that these proteases often act in larger multiprotein complexes, which define their proteolytic activities in time and space.
In the present review we focus on new developments with regard to matrix metalloproteinases and related metalloproteinases involved in angiogenesis. For a general overview of the role of other pericellular proteases in angiogenesis the reader is referred to previous reviews 6, 7, [10] [11] [12] [13] .
MMPs AND RELATED METALLOPTROTEINASES

MMPs AND MT-MMPs
Matrix metalloproteinases (MMPs) belong to a multigene family of zinccontaining endopeptidases [14] [15] [16] 26 .
ADAMTSs
A second group of MMP homologues is the ADAMTS family, which has 19 members in man 22, 27 . They have proteolytic activity and are produced as secreted proteins, many of which bind to matrix proteins. ADAMTS-1 is dispensable for angiogenesis during murine development 28 . However, in specific conditions ADAMTS-1
and -8 reduced VEGF-enhanced angiogenesis, such as in the chick chorioallantoic membrane and bFGF-enhanced angiogenesis in the cornea pocket (see 29 for review).
While earlier attention has been given to the potential inhibitory role of two thrombospondin-domains in the C-terminal part of ADAMTS-1 29 , recent data show that ADAMTS1 cleaves thrombospondin-1, and thereby generates anti-angiogenic peptides 30 .
ENDOGENOUS INHIBITORS OF METALLOPROTEINASES
The importance of metalloproteinases in angiogenesis is underlined by the impact of deletion of an inhibitor of metalloproteinases RECK. RECK is a GPI-anchored 34 . Only TIMP-3 is sequestered to the cell membrane and the extracellular matrix, to which it binds with both its amino-and carboxy-terminal domains 35 . At the cell membrane it associates with the glycosaminoglycan, in particular heparan sulfates, and may play a role in the regulation of ADAM-17 36 .
TIMPs also have biological effects unrelated to metalloproteinase inhibition.
TIMP-3, but neither TIMP-1 nor TIMP-2, is involved in binding to the VEGF receptor-2 (KDR) and competes for de binding of VEGF to this receptor 37 . Overexpression of TIMP-3 can induce apoptosis. TIMP-1 and TIMP-2 display anti-apoptotic properties and indirectly induce cell signaling 38, 39 . 
PIVOTAL ROLE OF MMPs AND MT-MMPs IN ANGIOGENESIS
A number of studies including gene deletions in mice have pointed to the essential role of MMP-2, MMP-9, and MT1-MMP in the onset of angiogenesis in tumors, development and bone formation [40] [41] [42] . Evidence has been provided that matrix degradation is an important aspect in their ability to stimulate angiogenesis. However, it should be noted that the activities of these proteases are complex and may include other pro-or anti-angiogenic effects as well, such as the activation of growth factors and cytokines, degradation of inhibitors, the recruitment of endothelial progenitor cells, and the generation of angiogenesis-inhibiting matrix-derived peptides (detail given below).
The impact of this complexity was illustrated with MMP-9. MMP-9 not only stimulates the onset of tumor angiogenesis, but subsequently also generates angiogenesis inhibitors, such as the collagen type-IV-derived fragment 'tumstatin', by which angiogenesis becomes retarded 43 . Whether MMP-19, which acts as a negative regulator of early steps in tumor angiogenesis and invasion 44 , acts in a similar way is not yet known.
When the abilities of various proteases to enhance capillary-like tube formation in a collagen-rich matrix were compared on the basis of deletion experiments, only MT1-MMP appeared indispensable for endothelial cells to form invading tubular structures, while MMP-2, MMP-9, their cognate cell-surface receptors β3-integrin and CD44, or plasminogen were not 45 . However, single gene deletions only identify those proteases that have unique properties, whereas proteases with crucial properties that are shared with comparable proteases may not be identified. 
PROTEASES AND THE PRO/ANTI-ANGIOGENIC BALANCE
Angiogenic growth factors and inflammatory cytokines can induce a number of pericellular acting proteases, including MT1-MMP, MMP-2, MMP-9 and u-PA. This is generally seen as a part of the repertoire of cellular activities that is switched on when proangiogenic growth factors have overruled angiogenesis-inhibiting factors. However, this unidirectional view on the relation between angiogenic growth factors and proteases has evolved into the insight that proteases themselves also contribute to fine-tuning of the activities of various growth factors that control the onset and progression of angiogenesis 6, 7, 9 .
ACTIVATION AND MODIFICATION OF GROWTH FACTORS
Several growth factors involved in angiogenesis require proteolytic processing to become active. Hepatocyte growth factor (HGF) is activated by the serine protease HGF activating factor and the transmembrane serine proteases matripsin and hepsin 46 . TGF-β can be activated by the action of plasminogen activators and thereby becomes able to modulate angiogenesis 47, 48 . Heparin-binding epidermal growth factor (HB-EGF) is released from its membrane bound precursor by ADAM-17 49 .
Growth 52 . Similarly, the properties of stromal cell-derived factor-1 (SDF-1) are modified by carboxy-and amino-terminal truncations (see below).
ECTODOMAIN SHEDDING AND RECEPTOR SIGNALING
The shedding of ectodomains of receptors and other membrane proteins has been recognized for a long time, but only during the last years it has become clear that ectodomain shedding is an initial step of the activation of specific receptors, such as Notch, ErbB-4 and Tie-1 53 . Notch-1 signaling plays a role in endothelial differentiation and embryonic and tumor angiogenesis 54 , while the angiopoietin receptor Tie-1 is indispensable for embryonic blood vessel formation 55 .
Binding of the ligands DeltaL4 and Angiopoietin-1 to Notch-1 and Tie-1, respectively, facilitates the proteolytic cleavage of the ectodomains of these receptors by ADAM-17 and ADAM-10 56,57 . After this initial proteolytic step, the remaining transmembrane and intracellular part is further processed intracellularly by the γ -secretase complex, in which the aspartate proteinase presenilin is the active protease 58 .
By this cleavage the cytoplasmic fragment of the receptor becomes available for cellular signaling and, in the case of Notch, transfer to the nucleus. Deficiency of ADAM-10, but not that of ADAM-17 resembles the early embryonal pathology of Notch1/Notch4 double knock-out mice suggesting a dominant role for ADAM-10 in mice 57 .
SHEDDING OF OTHER PROTEINS
Various cytokines and growth factors are produced as an extracellular part of a membrane integrated proform. After proteolytic shedding, these factors perform their paracrine action. TNFα is released by ADAM-17, also known as TNF-converting enzyme (TACE). Furthermore, by shedding of EphA2 and EphA3 ADAM-10 generates cleaved soluble Eph receptors, which inhibit tumor angiogenesis in mice 59 . Other examples are the shedding of pro-angiogenic soluble E-selectin 60 , shedding of urokinase receptor (uPAR) by MMP-12 61, 62 , which generates a cleaved soluble-uPAR with chemotactic properties for leukocytes and progenitor cells (see below), and shedding of IL-6 receptors by ADAM-10 and ADAM-17 63 , which facilitates IL-6 signaling in endothelial cells 64 .
MT1-MMP can shed soluble Semaphorin-4D from its membrane-bound form on tumor cells, which interacts with plexin-B1 on endothelial cells and induces pro-angiogenic chemotaxis of these cells 65 .
These examples suggest that the shedding of ectodomains from membrane proteins is a rather general mechanism. As potent biological modifiers can be generated, it is likely that proteolytic shedding is a tightly controled mechanism. In addition to several ADAMs and MT-MMPs, membrane-bound serine proteases 13 may be involved. These fragments are also indicated as matrikines and have been the subject of various reviews 6,9,66 .
ENDOGENOUS INHIBITORS GENERATED BY PROTEASES
PERICELLULAR MMPs AND INVADING CAPILLARY SPROUTS
Once properly activated, endothelial cells degrade their basement membrane and . Shear forces and angiopietin-1/Tie-2 signaling suppress its transcription 75, 81 .
MT1-MMP AT THE INVADING FRONT
There is ample evidence that MT1-MMP is present at the leading tip of invading cells 20, 74, 82 . However, how can proteolytic activity at the cellular front help a cell to move forward? The cell makes cellular protrusions with integrin-mediated matrix contacts to enable it to pull itself forward. However, once this process is initiated, cell movement will be hampered by existing cell-matrix interactions, which keep the cell fixed in its original position, or by the extracellular matrix meshwork, usually collagen, that allows entrance of the thin cellular protrusions, but not the thicker cell body.
For tumor cells invading a 3D-collagen matrix Wolf et al 83 observed that, while MT1-MMP is present at both the anterior adhesive and posterior proteolytic zones of the leading edge of invading cells, its collagenolytic activity was only present at the latter zone (compare Figure 2) . This enabled the cell to generate pulling force between the leading end and the cell body without loosing grip, while movement was allowed in the adjacent area by proteolytic activity. Proteolytic activity was particularly present at sites where the existing collagen fibers interfered with the forward movement of the cell 83 .
Such a mechanism requires that MT1-MMP activity will be masked until it has moved from the tip of the protrusion to the adjacent proteolytic zone. Mechanisms that may contribute to such masking are a two-step proteolytic processing 84 , which delays Once MT1-MMP activity is available, both MT1-MMP and MMP-2 can degrade various matrix proteins 6, 20, 74 . MT1-MMP has a broad-spectrum proteolytic activity towards a variety of ECM proteins including collagens, fibronectin and laminin-5. Its ability to activate MMP-2 and MMP-13 extends its effect on matrix degradation 15, 20 .
Furthermore, MT1-MMP activity can cause enhanced intracellular activation of Src and ERK and VEGF gene expression 86, 87 .
INTERNALIZATION OF MT1-MMP
One of the additional substrates for proteolysis by MT1-MMP is CD44H, which binds both to the hemopexin domain of MT1-MMP and indirectly to the actin cytoskeleton 74, 88, 89 . The potent proteolytic activity of MT1-MMP at the cell surface is self-limiting, as MT1-MMP is subsequently internalized. This process is inhibited when the cleavage of CD44H is prevented by mutation 88 . Once MT1-MMP is internalized it can be degraded in the lysosomes or shuttled back to the plasma membrane depending on further regulatory steps (Figure 2 ). MT1-MMP can be internalized via clathrin-coated vesicles or via caveolae. Galvez et al 90 reported that internalization of MT1-MMP via caveolae was required for the migration of endothelial cells in a collagen substrate.
However, in other cells requirement of clathrin-mediated uptake was indicated as main mechanism of uptake, in which the short cytoplasmic tail of MT1-MMP played a role 91 .
Whether the different internalization pathway in endothelial cells mainly reflects the abundant presence of caveolae in these cells is not yet known.
Recent data indicated that a Src-dependent phosphorylation at Tyr573 in the short cytoplasmic domain of MT1-MMP was required for sphingosine-1-phosphate-induced cell migration in endothelial cells 87 . Palmitoylation at the adjacent Cys 574 was found to be essential for MT1-MMP-dependent cell migration and clathrin-mediated internalization 92 , suggesting that the cytoplasmic domain must be aligned along the membrane for this activity.
Interestingly, no information is presently available whether MT1-MMP activity disappears during MT1-MMP internalization. A report suggesting an intracellular action of MT1-MMP suggests that this is not necessarily the case 93 .
OTHER MT-MMPs
Other MT-MMPs also contribute to cell migration and collagenolysis 94 .
Comparable to MT1-MMP, the membrane spanning MT2-and MT3-MMP induced endothelial tubules, while the GPI-anchored MT4-MMP was unable to so 94 . MT3-MMP, rather than MT1-MMP was involved in the formation of tubular structures by human endometrial microvascular endothelial cells, while their foreskin counterparts used MT1-MMP 79 . MT2-MMP may also be involved in the endometrium 95 . Interestingly MT2-MMP can activate MMP-2 independent of TIMP-2 96 .
PROTEASES AND THE RECRUITMENT OF BONE MARROW DERIVED CELLS
There is ample evidence that leukocytes and endothelial progenitor cells can additionally contribute to angiogenesis 5, 97 . Monocytes and mast cell progenitor cells produce various pro-angiogenic factors 97, 98 . This is also the case with a special population of CD34+ cells that can acquire endothelial-like properties, such as the expression of VEcadherin and VEGF receptor-2, and tentatively are indicated as EPCs. EPCs are thought to accelerate the progression of angiogenesis 5, 99 , and their absence or dysfunction has been associated with impaired vascularization in cardiac and diabetes patients 100 .
According to recent data, most of these cells are monocytic in nature, and only a small proportion represents real endothelial progenitor cells 101, 102 . Several proteases, including MT1-MMP, MMP-9, uPAR-bound u-PA and cathepsin-L, play a role in the mobilization of various types of progenitor cells in the bone marrow and in the recruitment of these cells into the areas of neovascularization 70, 76, 103 . 
MMP-9 AND MOBILIZATION OF PROGENITOR CELLS
With respect to the mobilization of various types of progenitor cells MMP-9 received special attention. Recruitment of progenitor cells from the osteoblastic niche into the vascular zone of the bone marrow requires Kit-ligand bioavailability 104 . This availability is facilitated by shedding of soluble Kit-ligand (sKitL) from its membranebound precursor by MMP-9 mediated proteolytic cleavage. In MMP-9-deficient mice the release of sKitL was impaired, and recruitment of hemopoietic progenitor cells delayed 104 . Similar experiments performed in eNOS-deficient mice demonstrated that NO is involved in VEGF-induced MMP-9 activation 105 . Indeed, NO enhances MMP-9 activity 106 . The release of sKitL by VEGF-induced MMP-9 mobilizes endothelial and mast progenitor cells in a comparable way 99 .
HOMING OF PROGENITOR CELLS AND ENTRY INTO THE ANGIOGENESIS
AREA
Under basal conditions a small proportion of progenitor cells is already released to the circulation. They will be attracted to areas of tissue repair and neovascularization or home back to the bone marrow. Chemokines, in particular SDF-1, play an important role in directing progenitor cells. Proteases enable the progenitor cells to enter a tissue 76, [107] [108] [109] .
Various reports describe the expression of MMP-2 and MMP-9 in peripheral blood and bone marrow CD34+ progenitors as well as cultured EPCs. Stimulation with TNFα, IL-8
or SDF-1 resulted in increased MMP levels, facilitating the migration of EPCs into
Matrigel plugs or transwell systems [107] [108] [109] . In addition to MMPs, EPC-derived cells produce u-PA/uPAR and various cysteine cathepsins 76, 110 . It is of interest to note that the activity of SDF-1 by itself can also be modified by proteolytic cleavage. The two isoforms of SDF-1, SDF-1a and SDF-1b, are both modified by the aminodipeptidase DPPIV/CD26, by which their heparan sulfate affinities and interactions with their receptor CXCR4 are reduced 115 . SDF-1a can also be shortened by carboxypeptidase N (also called TAFI) 116 , which further reduces the affinity for heparan sulfates. MT1-MMP, MMP-1, -3, -9 and -13 can cleave and thereby inactivate SDF-1 or markedly weaken the binding to its receptor CXCR4 117 . Once the new microvessels become perfused, the increased demand on blood supply will induce outward remodeling of the proximal vessels, which requires MMP activities as well 20 .
MATURATION OF NEWLY FORMED VESSELS
PERSPECTIVE
This review has mainly been focused on MMPs and ADAMs, of which several members play a pivotal role in angiogenesis. MMP-2, MMP-9 and MT1-MMP and their inhibitor RECK are a prerequisite for the development of proper blood vessels. Their deficiencies result in death or major defects during embryonic or perinatal development.
Similarly, deficiencies of other proteases including the serine proteases prothrombin, 122 . Deficiency of MMP-13 retards bone fracture healing and its associated angiogenesis 123 . Aminopeptidase-N deficiency affects neovascularization in oxygeninduced retinopathy 73 .
Proteases and their products contribute to the fascinating complexity by which the formation and adaptation of the vascular system is regulated. Proteolytic activities during matrix remodeling and cell migration have been recognized earlier and indicated as targets for therapeutic intervention in rheumatoid arthritis and tumors 124 . However, initial attempts were unsuccessful, because understanding the contributions of proteases was incomplete 125 . Modification and generation of growth factors and cytokines, ectodomain shedding and receptor signaling, and generation of matrikines are new areas, which only recently received the attention that they deserve. Better understanding of the various activities of proteases and development of more specific inhibitors may help designing more tailor-made treatments. 
